Safety, tolerability, pharmacokinetics and pharmacodynamics of DS 1501 in healthy young subjects and healthy postmenopausal women

Trial Profile

Safety, tolerability, pharmacokinetics and pharmacodynamics of DS 1501 in healthy young subjects and healthy postmenopausal women

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs DS 1501 (Primary)
  • Indications Osteoporosis
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 22 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top